On October 9, 2020 Allarity Therapeutics A/S ("Allarity" or the "Company") reported that following the Company’s name change from Oncology Venture A/S to Allarity Therapeutics A/S, the Company will be trading under its new short name ALLR from Monday, 12 October 2020 (Press release, Allarity Therapeutics, OCT 9, 2020, View Source [SID1234569150]). The share’s ISIN code, DK0060732477, will remain unchanged.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Concurrently, the Company’s listed equity rights (warrants), TO 2, will change short name from OV TO 2 to ALLR TO 2. The ISIN code of this instrument, DK0061153657, will also remain unchanged.

On October 9, 2020 Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, reported preliminary unaudited revenue for the third quarter of fiscal year 2020 (Press release, Biofrontera, OCT 9, 2020, View Source [SID1234568552]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Biofrontera-Group generated total preliminary unaudited revenue of approximately EUR 20.8 to 21.0 million in the period from January 1st to September 30th, 2020. This corresponds to revenue growth of about 9% compared to the same period last year (EUR 19.1 million).

Thereof, total preliminary unaudited revenue for the third quarter amounted to between EUR 4.7 and 4.9 million, about 9% less than in Q3 2019 (EUR 5.2 million). Preliminary unaudited Q3 2020 revenues from pure product sales were between EUR 4.6 and 4.8 million, which corresponds to a 6% decline compared to EUR 5.0 million in Q3 2019.

In the traditionally weak third quarter due to seasonality, the Company generated between EUR 2.7 and 2.9 million from sales of Ameluz in the USA, compared to EUR 3.4 million (approx. -19%) in Q3 2019. Product sales from Xepi contributed about EUR 45 thousand, compared to EUR 0.1 million in the same reporting period in 2019.

In Germany, sales revenues in the third quarter increased by about 36% to between EUR 1.5 and 1.7 million. In the rest of Europe, the Company generated product sales of about EUR 0.4 million, compared to EUR 0.5 million (approx. -15%) in the same period last year.

Despite the economic and social impact of the corona pandemic, product sales in the German market increased significantly compared to the previous year. Revenues in the United States were negatively affected, where the crisis continues to have a much stronger impact on the market. As in previous years, however, the Company continues to see the fourth quarter as the key revenue driver for its growing business in all markets.

On October 9, 2020 Creative Biosciences, a Guangzhou oncology testing company, reported that it raised $90 million in a Series C funding led by Tsing Song Capital (Press release, Creative Biosciences, OCT 9, 2020, View Source [SID1234568282]). In 2018, Creative Bio was approved by China’s NMPA to market Colosafe, a stool-based diagnostic test for colon cancer. The company says Colosafe costs less than half the US competition but has a higher detection specificity. Creative was founded by the research team led by Professor Hongzhi Zou at Sun Yat-sen University. It will use the proceeds to develop early screening and point-of-care testing products for lung, bladder, liver and cervical cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 9, 2020 Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company ("Lilly",NYSE: LLY), reported that HALPRYZA (rituximab injection), a recombinant human/murine chimeric monoclonal antibody drug co-developed by Innovent and Lilly, has been officially approved by the National Medical Products Administration (NMPA) of China for patients with diffuse large b cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) in China (Press release, Innovent Biologics, OCT 9, 2020, View Source [SID1234568276]). HALPRYZA (rituximab injection) is Innovent’s fourth monoclonal antibody drug approved by the NMPA following TYVYT (sintilimab injection), BYVASDA (bevacizumab injection) and SULINNO (adalimumab injection). It is also the second monoclonal antibody approved by NMPA that was co-developed by Innovent and Lilly after the approval of TYVYT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical efficacy and safety of rituximab in CD20-positive non-Hodgkin’s lymphoma have been confirmed in several large-scale clinical trials. Rituximab injection, approved by FDA in 1997, is approved for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA)，granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and moderate to severe pemphigus vulgaris (PV). The efficacy and safety of rituximab have been well recognized worldwide. HALPRYZA (rituximab injection) is a recombinant human/murine chimeric monoclonal antibody drug co-developed by Innovent and Eli Lilly. The launch of HALPRYZA (rituximab injection) will provide Chinese patients with high-quality and relatively more affordable rituximab injection.

Dr. Hui Zhou, Vice President and Head of Oncology Strategy and Medical Sciences of Innovent, stated: "HALPRYZA (rituximab injection) is another example of our success with the National Major New Drug Innovation and Development Projects and the fourth monoclonal antibody drug approved by the NMPA following TYVYT (sintilimab injection)，BYVASDA (bevacizumab injection), and SULINNO (adalimumab injection). We hope to bring this high-quality drugs to more patients in need in China as soon as possible."

Dr. Li WANG, Senior VP of Lilly China and Head of Lilly China Drug Development and Medical Affairs Center, stated: "We’re excited that Lilly and Innovent strategic collaboration has reached another success. Lymphoma is one of the malignant tumors with rapid growing incidence. However, the survival rate is also relatively higher than other tumor types when having appropriate treatment. The approval of HALPRYZA (rituximab injection) will bring a new option to Chinese Lymphoma patients, help them to improve quality of life & prolong their survivals."

About Malignant Lymphoma

Malignant lymphoma is one of the most common hematological malignancies in China. It is one of the top ten malignant tumors with high morbidity and mortality. In recent years, the incidence of malignant lymphoma has been rising. According to histopathology, lymphoma can be divided into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL), of which NHL accounts for the majority. NHL is a general term for a series of related but different lymphoid malignant tumors. Most (80-85%) originates from B cells. The rest originate from T cells or NK cells. More than 95% of B-cell non-Hodgkin’s lymphoma cells express CD20. The incidence of NHL increases with age. The most common type of NHL in China is diffuse large B-cell lymphoma (DLBCL), accounting for 40-50% (about 30-40% in Western countries). DLBCL is a moderately malignant to highly malignant invasive lymphoma that progresses rapidly and leads to the death of patients within a few months without treatment.

About HALPRYZA (rituximab injection)

HALPRYZA is rituximab injection and a recombinant human/murine chimeric monoclonal antibody drug. Rituximab binds to the CD20 antigen on the surface of B lymphocytes and mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Normal and malignant B cells are targeted for destruction by the antibody, thereby achieving anti-tumor and immunosuppressive therapeutic effects.

On October 9, 2020 Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, reported that Athenex Oncology, a U.S. based division of Athenex, launched Your Guide to Facing Metastatic Breast Cancer — a free, first-of-its-kind resource offering comprehensive lifestyle guidance to people living with metastatic breast cancer (MBC) (Press release, Athenex, OCT 9, 2020, View Source [SID1234568275]). The Guide provides evidence-based recommendations for increasing resilience, reducing stress, maintaining good dietary and sleep habits, managing inflammation, and other tips to improve quality of life while living with MBC. The Guide can be ordered at www.AthenexOncology.com/patient-resources.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The launch of Your Guide to Facing Metastatic Breast Cancer is timed to coincide with MBC Awareness Day on October 13. The Guide, which is created by health and wellness company Viver Health, complements Facing MBC Together, a public education and patient support program that Athenex Oncology launched in June 2020 to provide practical and emotional support to people living with MBC.

"Introducing Your Guide to Facing Metastatic Breast Cancer during National Breast Cancer Awareness Month underscores Athenex Oncology’s commitment to meeting the needs of the metastatic breast cancer community," noted Timothy Cook, senior vice president, global oncology at Athenex. "Our continued provision of practical resources that promote health and wellness reflects our view of individuals as whole people, not as ‘patients.’ While the lifestyle tips in the Guide can be useful to anyone, they are designed to be especially helpful to those who are living with metastatic breast cancer."

The recommendations in the Guide are based on extensive research showing that a health-oriented lifestyle – one that encompasses a healthy diet and nutrition, exercise, stress reduction, inflammation management, and adopting coping mechanisms to become more physically and emotionally resilient – may improve overall survival and quality of life following a breast cancer diagnosis.1-6 The Guide has distilled and translated those research findings into simple and easily understandable information that people living with MBC can adopt and implement on their own.

"Living with metastatic breast cancer is about more than just taking your medicine and keeping all your doctor’s appointments," commented Beth Baughman DuPree, M.D., a board-certified general surgeon specializing in diseases of the breast, and a medical advisor to the development of the Guide. "It’s about being mindful and taking an active role in your own care, while also finding ways to bring meaning to your life, whether through connecting with friends, creating art, communing with nature, or relieving stress through yoga, tai chi, quigong, reiki, or just plain laughter. Your Guide to Facing Metastatic Breast Cancer is designed to help you find your own path to health, wellness, optimism, and inner strength."

Dr. DuPree, who is the medical director of the oncology service line at Northern Arizona Healthcare, vice president, health at Holy Redeemer Health System in Pennsylvania, as well as founder and president of the Healing Consciousness Foundation added, "While the Guide was created before the global COVID-19 pandemic struck, its recommendations can be particularly useful during these difficult times, when people with metastatic breast cancer feel even more isolated than usual."